Choroba niedokrwienna serca


! " #
$% '( #) *+
,33 8 4 -0 858350210 2.445 -3 0--44 324-8 58 23 85256
43-.83/4
57-48 32808.435548-3324-8 58-83/-8 4.48891%
:8%; #< = < > ?@< A B < ! C DE "#!= B>F
G 25/44H 98-8IJ K
G 4519- 32.-IL K.584M58-8NO385/-8
G 4519- -832. ILPK
G 2344H50332 58IQRK
G 388324-48%
:5%S "T! U A ! V ! = UB> ! C DE " #F
G .58 8948.43-44H3-2348 58IWLK
G .58 894038--806 640
G 8358-854 252
G 4-- 54 254 845
G .443 34/45-0 00 - 3/-3
X%Y <@#<@ @ *+
G # @ #<@Z! Z# !@#[C ?<@#\2 4 8.8/- -806]2580]
5484-8-438/K
G 880838 4
G -884-- 323-
G 29 38 0N5588085033
G -8450-4.83
G 858434.83
G .588 48- 83^383-0]48-0
G -845 344H]8352 3/- 3 2/8
W0-- 500854 423898900%
! Z# !_
`% + UB ! CDE "#!=N38-0 324-2 5403 0-81 - ) !@6
a b>
W85835030857/2898 4 46 8 44/ -448 2.48 8] 85835]23 4 -]
8358-8].543 -48- 57/2%
a< U < @BCU AP8 23 8525-850332 583 8-3 .4 388-86
- 34 --44H/350 -8324-8 58]^8/-8543-I5-350K%
#a !@ > Ec T?
O254854 254880^2- 8324-8 58%
d% e> "@( #) *+! VU=fg;h
$Ki543- 835038- 58I-890 4- 540]-89 835038- 519-8K
:Kj98 8.548I82-854/-8]1--8. 345K
8K j98 8.548 0948I4 98]385/-8]84354-8K
5Kj98 8.548-8 0-4 2548I1--8i5-338/8K
K j98 8.548- 385/-8I8898589810]4358- 084/-44H 648N57/.48 8
25 1 2 2 4-03 8.435548-3324-8 58-83/-].5884.4845-
3450 285..90340K
XKk889324-8 58I4350.55030K
`KWPO.48.4381- 084/-44 519-8
dKWPO.48.4381-385444 I8525-850332.5 48 - 8K
12345678945838 4 4 8
2 84 8 9483 8 4 2 4 4 9 4 4! 45
44358 8
4 4843 488" #8 5883 $% 232 485 3 922 5 2
5 82
3 3 34 5 $
8 5
&8 452 44 2'53''4538 8!
($ *+,+-/012+
383 86
4
4 85 8 8 "855 4
4 835'58" 3 8 2 4"83589
4 2 2
4 25 8 8 4 4
64 8 889 6
4 889 94# 89" "744 "2 89 5
8 24#8#8 !
4 94# 3 $44744 "2 44 4 5 4 !
9 8 6
4 889 "844 85354 2 2 4 : 3 8 :
4 8
4 48 8 2 83 4# ' :3
5848" ;<" $
4 94582 8 383
8 5
4 8 8 : 4 : 2 85353 5 #" 5 !
8
64 4 8 6
4 8 88 5 "43
4
4 =>?
4 4 " "855"85 " #8 58 88'4'458348@>47%:344 8:
3 5
"4 4 8!
A 63B@1:34"4 8
5
78 852 8889
2
& 94889 5 5
4 8
C$ D+E+FGEHE+IJH,0
+
K$ L3553
885 =>?6
4 "8 45 : 428"8 88
4 4 5 4 4444"45 L:LL:LLL3 8
4 4
4 38 3 48: 5 488 48
5 484"45 38 3 4"45
M012HNH2OHEF+FG,PEHQHRSJ1TU0FGVFG,PEHQHRS/012+W
0 F + 0 F
X$ Y0ZGG[
F2+
\ 44#8 583 8 834 : 35" 4 4 424# 8 58844" 44
43 4
34 : 2 4 5 3 3 43588485 38 5 4# 4
9 8 8
45 8 43 "34 $
5 8
34"4#8" 23 84838 8 8 5 0
48@9! 58 3 3"89 2 432"34 42 342VNG1,HIFP/N+E0J
NH[]FHR2G]G^IH,0[/012+W_
0 F
;$ `1aP2aPFPFG,PEHQHR2G/012+
0 F
8!3543 2 4 25 4# " #8 58
!& 3254 5 83 45 5 # 4
!& 3254 5 3 45 5 4 3#4
4
!& 3"894 5 3 b" 4 4535 :"89
84834#8" #8 58854 8
!&825 8532 5 4 8
"
cOdMV,IP]a+,+-eF+E2GFGFGIfIFGa0e,+EPa+/I+,JH,0
W R00 2
6J+1EG]GN+IGea+N+QFG]GRFG/012+:' 88 5 8:3 853 :439#8:
H H 0 00 f + 8 " 4
25 8:8" 448: "4 54"838:3"488 58:8 8 88 4 5 8:#28 4
4 8
5 4 8$
12345678945838 4 4 8
!"#$%&"& ()*#"
+, - 44.4548/05844.4548/4124.4548
2, 438/05 -9
5 8
, 34526 7 2547/34526 754 2547/. 868
" #$ %& "&89 #$& &:&(&$
;(<#$#=
& >(
?@AB8534.4083/ 54-9 8 8
4889/68934526 883
683C66 33 /834 65 464. 808-62 538/
D6
83 8453-6/.38-6 0D6D 35264C D 6 3
8 8 5
" #$ %& "&89;( $& &:&(&$
;(<#$#= &>(
5 0926/ 834 38.046838 58/83453D3640926/
838 0680926 4-21 4-4864889058 4.454
35E3 -6/05436
683C66 0926
" #$ %& "&89&FG &:&(&$
68 DC 54 87 D 46 434-64C 4124.E5H86 434-64CI058 4.454 3683D03 .
6 434-64C 4.454- ,
J >& "&$ "#$%&"&89#(
K G" ! G(<&$ H204C-3468588 252,
L 8534.4083854 35648
L 889.DC68 58
K G" !(&L 8 86 5805 4 53 H8 87 808-6 4 538,
L 38.046838 58
L 6343-66 .DC68 58
L 05543.DC68 58/9E66/68 4.E54 60 8534.408380554348/683C66
3D36 /4-8 644/8.4-4348
M N>&O#"#<
P 43 6 58
A083 04.64C .6234 58
P983Q11 8405468 P983 0E92-64 . 86.44.06846
H83803846,
Q368432 434 R0E5414344 S TQ 58 19D36 494 45414
UV4652-8346WXY5 0345E
@ 434-64CI 58
A083 5232 58 34689.252 8.874.. 86.44.06846/3E5.87883866
8,04058 I058D 588404.04
1, D 4I C66 3D36 C66 0552
, 548I5 34 8Z64 Z44468573E
12345678945838 4 4 8
7 8 4 8 6
38 6
5
8 58 8 35 8
8
543 !3" 25# 58 25 4" 9
4 8
5543 !"8 58
$%4&4 6
5434%!3" 5 5'(' 29&)11*845 8
4 8
435 88 +& 3%285 29& #92 *29&)11*845 8
4 5 8 8
,52 8 8 8 4 8 5#%2'5 5#-58 &9 43!2342*
4'4 8 5
&8 29 82&4&83444%'(8'3 4&4 5.3' !5 '4 8%25+
82 8
/8 4%5!#* &43 !"8 58*8%25 8 343 0.)4 8 !4%581245678982
5 4 3 :
;<8=818>678?
@. A1B>CD>898E8=8>6B5F>C48D8G;FH6=;:
: 6 6 5
/ 8'9 832 5'( 29 &45 838 85'�
# 4 2
I2 4"- 948
I2 4"-324534 4
J88&48&2 4"-4 8/83 885&80
K8 /4 04& 3 "24 & /5 ! 8 4 3
28 5
! 5 4 0.
L 3
458 92
832 38 4
5
, 2 493 58
888
M# 9 *% 4"-
4
M8&8* 438 9&8 #58
4
$%8 &44" 5
$ 54& 8 29& 4854
8
$%5! 9
2
3' 85&4
5
N. A1B>CO=:>898E8=8>6B5F6>C48D58G;FH6=;:
:
/ 8'9 832( 484%4& 06
# 4
$%5! 4%4&4 *5 ! &48 89
8
P4 5 (9 *4%8 '34%44
5
P4 ! '34% "&4 / #9'34% 83 0845 94
5 5 44
854"- 548 '34%
5
J 358
2
P4 ! 4 4%#&%52 8*4%8 943
%88
M# 8&%522*2&4"*%588 33/432' 8 454 8 Q8
2 !
85&880
L83544"-9 8
4 2
R. S:=4FEFO:TF
8 8 6
U. V:4:5F484:T98>6FD6;W65F6
:
12345678945838 4 4 8


Wyszukiwarka

Podobne podstrony:
Kardiologia praktyczna 3 Choroba niedokrwienna serca (2)
F4 Choroba niedokrwienna serca
LEKI W CHOROBIE NIEDOKRWIENNEJ SERCA
Abramczyk M [red] Przyczyny hiperproinsulinemii u chorych na cukrzycę typu 2 z chorobą niedokrwie
choroba niedokrwienna serca cz2
Farmakologia ćwiczenia 4 Leki poprawiające pracę serca Leki stosowane w chorobie niedokrwiennej
Wiek a efekty długo terminowego trningu kardiologiicznego u pacjentów z chorobą niedokrwieną serca
Choroba Niedokrwienna Serca
Choroba niedokrwienna serca(1)
choroba niedokrwienna serca 4
Farmakoterapia choroby niedokrwiennej serca
leczenie choroby niedokrwiennej serca

więcej podobnych podstron